drugset / Trial / NCT00648193

Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg

NCT00648193

Phase 0 Completed 36 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to investigate the bioequivalence of Mylan's paroxetine hydrochloride 40 mg tablets to GSK's Paxil® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose administered under fasting conditions to healthy adult volunteers.

Timeline

Start
2006-12
Primary completion
2006-12
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 40 mg Oral

Indications

No indication recorded.